{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-26-000060","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2026-07-30T12:06:25+00:00","discovered_at":"2026-07-30T12:10:01.992257+00:00","generated_at":"2026-07-30T12:10:10.720515+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alnylam Q2 product rev $1.17B (+74% YoY); cuts FY TTR guidance to $4.2-4.5B","bullets":["Q2 2026 net product revenues $1,172M (+74% YoY); TTR franchise $1,030M (+89% YoY).","GAAP net income $164.5M ($1.23 diluted EPS) vs loss of $72.2M in Q2 2025.","Full-year 2026 TTR revenue guidance revised down to $4.2-4.5B from $4.4-4.7B (75% growth at midpoint).","Rare disease revenues $142M (+11% YoY) from GIVLAARI and OXLUMO.","Initiated Phase 2 trials for ALN-6400 (von Willebrand) and mivelsiran (Down syndrome Alzheimer's)."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-26-000060","json":"https://secwatch.observer/filing/0001178670-26-000060.json","markdown":"https://secwatch.observer/filing/0001178670-26-000060.md","text":"https://secwatch.observer/filing/0001178670-26-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/0001178670-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T12:10:10.720515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}